Moreover, we observed reduced expression of Ki‐67 (a tumor proliferation marker) and STAT3 in piR‐RCC overexpression or stattic treatment groups alone compared to the control group, with even lower expression in piR‐RCC overexpression and stattic combination treatment group (Figure 6J). The gene discussed is STAT3; the disease is neoplasm.